Tory Sullivan, MD
Dermatology · North Miami Beach, FLNPI 1639137169
Payments from drug & device makers
Across 1,501 payments — averaging $1974.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$622K
- Incyte Corporation$600K
- AbbVie$576K
- Bausch Health US, LLC$245K
- Sanofi US Services Inc.$230K
- Novartis$187K
- plus $504K from 29 others
Across 45 payments — averaging $3642.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$113K
- Arcutis Biotherapeutics, Inc.$28K
- AbbVie$11K
- Daiichi Sankyo Company LTD$9K
- Bausch Health US, LLC$2K
- Daiichi Sankyo Inc.$664
- plus $2 from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 91 | $621,940 |
| Incyte Corporation | 654 | $599,576 |
| AbbVie(2 entities) | 354 | $575,502 |
| Bausch Health US, LLC | 36 | $245,255 |
| Sanofi US Services Inc. | 18 | $229,810 |
| Novartis | 25 | $186,871 |
| Pfizer | 61 | $161,006 |
| Acrotech Biopharma Inc. | 15 | $93,154 |
| VYNE Pharmaceuticals Inc. | 26 | $83,718 |
| Eli Lilly | 8 | $69,469 |
| LEO Pharma AS | 15 | $30,102 |
| UCB SA | 5 | $23,598 |
| Boehringer Ingelheim | 2 | $15,013 |
| Amgen | 4 | $12,507 |
| Arcutis Biotherapeutics, Inc. | 1 | $4,970 |
| Galderma Laboratories, L.p. | 24 | $3,261 |
| UCB Biosciences Inc. | 14 | $1,741 |
| Johnson & Johnson | 39 | $1,507 |
| Daiichi Sankyo Inc. | 27 | $1,183 |
| Boehringer Ingelheim International GmbH | 1 | $1,085 |
| Sanofi | 28 | $853 |
| Regeneron Healthcare Solutions, Inc. | 12 | $306 |
| Lilly USA, LLC | 7 | $260 |
| UCB, Inc. | 6 | $171 |
| LEO Pharma Inc. | 6 | $123 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $121 |
| Bristol Myers Squibb | 3 | $79 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Genentech USA, Inc. | 3 | $59 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Encore Dermatology Inc. | 1 | $23 |
| Prugen, Inc. Pharmaceuticals | 1 | $18 |
| EPI Health, LLC | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Organon | 1 | $13 |
How this compares
$2,963,416 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in North Miami Beach
- Michael SherlingLake Worth$78.9M
- Seth FormanTampa$28.2M
- Thomas TaylorTampa$13.6M
- Frank DonHallandale Beach$7.5M
- Francisco FloresMiramar$6.7M
- Hector Wiltz JrMiami$6.4M
- Javier Alonso-LlamazaresCoral Gables$5.6M
- Eduardo WeissHollywood$5.5M
- Francisco KerdelMiami$5.1M
- Jason SluzevichJacksonville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.